

EXAMPLES OF NOTABLE REFERENCES ON:

Pharmacokinetics/Pharmacodynamics of antimicrobials

1. Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H., and Drusano, G.L. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. *J Antimicrob Chemother.* 55(5): 601-7.
2. Lodise, T.P., Lomaestro, B.M., and Drusano, G.L. (2006). Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy.* 26(9): 1320-32.
3. Jacobs, M.R. (2003). How can we predict bacterial eradication? *Int J Infect Dis.* 7 Suppl 1: S13-20.
4. Gillespie, E.L., Kuti, J.L., and Nicolau, D.P. (2005). When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. *Conn Med.* 69(4): 203-10.
5. Barger, A., Fuhst, C., and Wiedemann, B. (2003). Pharmacological indices in antibiotic therapy. *J Antimicrob Chemother.* 52(6): 893-8.
6. Boak, L.M., Li, J., Rayner, C.R., and Nation, R.L. (2007). Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. *Antimicrob Agents Chemother.* 51(4): 1287-92.
7. Jacobs, M.R. (2001). Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. *Clin Microbiol Infect.* 7(11): 589-96.
8. Pea, F. and Viale, P. (2006). The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? *Clin Infect Dis.* 42(12): 1764-71.
9. Nightingale, C.H., Murakawa, T., and Ambrose, P.G., *Antimicrobial pharmacodynamics in theory and clinical practice.* Infectious disease and therapy ; v. 28. 2002, New York: M. Dekker. x, 416.
10. Alvarez-Lerma, F., Grau, S., and Gracia-Arnillas, M.P. (2006). Gram-positive cocci infections in intensive care: guide to antibacterial selection. *Drugs.* 66(6): 751-68.
11. Rybak, M.J. (2006). The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clin Infect Dis.* 42 Suppl 1: S35-9.
12. Moise-Broder, P.A., Forrest, A., Birmingham, M.C., and Schentag, J.J. (2004). Pharmacodynamics of vancomycin and other antimicrobials in patients with *Staphylococcus aureus* lower respiratory tract infections. *Clin Pharmacokinet.* 43(13): 925-42.
13. DeRyke, C.A., Lee, S.Y., Kuti, J.L., and Nicolau, D.P. (2006). Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. *Drugs.* 66(1): 1-14.
14. Frei, C.R., Hampton, S.L., and Burgess, D.S. (2006). Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis. *Clin Ther.* 28(7): 1035-40.
15. Fridmott-Moller, N. (2002). How predictive is PK/PD for antibacterial agents? *Int J Antimicrob Agents.* 19(4): 333-9.
16. Kiffer, C.R., Mendes, C., Kuti, J.L., and Nicolau, D.P. (2004). Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. *Diagn Microbiol Infect Dis.* 49(2): 109-16.
17. Noreddin, A.M. and Haynes, V. (2007). Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. *Drugs Aging.* 24(4): 275-92.
18. Roberts, J.A., Paratz, J., Paratz, E., Krueger, W.A., and Lipman, J. (2007). Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. *Int J Antimicrob Agents.* 30(1): 11-8.

19. Zelenitsky, S.A., Harding, G.K., Sun, S., Ubhi, K., and Ariano, R.E. (2003). Treatment and outcome of *Pseudomonas aeruginosa* bacteraemia: an antibiotic pharmacodynamic analysis. *J Antimicrob Chemother.* 52(4): 668-74.
20. Lipman, J. (2000). Towards better ICU antibiotic dosing. *Crit Care Resusc.* 2(4): 282-9.
21. Schentag, J.J., Klugman, K.P., Yu, V.L., Adelman, M.H., Wilton, G.J., Chiou, C.C., et al. (2007). *Streptococcus pneumoniae* bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study. *International Journal of Antimicrobial Agents.* 30(3): 264-269.
22. Zhanel, G.G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., et al. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant *Streptococcus pneumoniae* simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. *J Antimicrob Chemother.* 52(1): 83-8.
23. Lewis, R.E. (2007). Pharmacodynamic implications for use of antifungal agents. *Curr Opin Pharmacol.* 7(5): 491-7.
24. Andes, D. (2004). Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. *Drug Resist Updat.* 7(3): 185-94.
25. Dodds Ashley, E.S., Lewis, R., Lewis, J.S., Martin, C., and Andes, D. (2006). Pharmacology of Systemic Antifungal Agents. *Clin Infect Dis.* 43(S1): S28-39.
26. Clancy, C.J., Yu, V.L., Morris, A.J., Snyderman, D.R., and Nguyen, M.H. (2005). Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. *Antimicrob Agents Chemother.* 49(8): 3171-7.
27. Lewis, R.E., Wiederhold, N.P., and Klepser, M.E. (2005). In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against *Aspergillus*, *Fusarium*, and *Scedosporium* spp. *Antimicrob Agents Chemother.* 49(3): 945-51.